brand new GSK shingles vaccine off to strong start in key U.S. market

GlaxoSmithKline’s brand new shingles vaccine – a priority product as the company strives to improve its drugs line-up – has won more than 0 percent U.S. market share just 5 months after its launch, prescription-tracking data show.

The healthy take-up comes at the expense of Merck’s older along with less effective product Zostavax, which has seen a slump in demand.

The U.S. Centers for Disease Control along with Prevention has recommended Shingrix over Zostavax in adults 50 years along with older, spurring demand for the GSK vaccine.

Deutsche Bank analysts said on Tuesday the prescription data to mid-March implied “a very strong launch”, even though the figures compiled by health information company IQVIA capture only 50 to 60 percent of the market.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

11 − 10 =